Due to the positive trial results, the anti-PD-1 antibodies nivolumab and pembrolizumab and the BRAF inhibitor dabrafenib, in combination with the MEK inhibitor trametinib, were approved for adjuvant treatment of melanoma patients by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Here, BRAF is linked to melanoma.